SCHEMBL266485

SCHEMBL266485

CC1CC(=O)N(Cc2cccs2)C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.64
ALDH1A1 P00352 5/20 0.44
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HSD17B10 Q99714 3/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
RXFP3 Q9NSD7 1/20 0.43
KDM4E B2RXH2 2/20 0.41
ALOX15 P16050 1/20 0.41
GFER P55789 1/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.41
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14146082 0.79 L3MBTL1 (0.61) L3MBTL1ALDH1A1MAPTMEN1KMT2A
SCHEMBL2449353 0.78 L3MBTL1 (1.00) L3MBTL1ALDH1A1MAPTGAASMN1; SMN2
SCHEMBL5240774 0.77 L3MBTL1 (0.78) L3MBTL1ALDH1A1MAPTMEN1KMT2A
SCHEMBL6612380 0.75 L3MBTL1 (0.67) L3MBTL1ALDH1A1MAPTMEN1KMT2A
SCHEMBL13485761 0.75 L3MBTL1 (0.74) L3MBTL1ALDH1A1MAPTKMT2AGAA
SCHEMBL16080214 0.74 HPGD (0.64) L3MBTL1ALDH1A1MAPTKMT2ALMNA
SCHEMBL434087 0.74 HPGD (0.64) L3MBTL1ALDH1A1MAPTKMT2ALMNA
SCHEMBL25244867 0.73 L3MBTL1 (0.47) L3MBTL1ALDH1A1MAPTMEN1KMT2A
SCHEMBL266674 0.73 MAPT (0.55) L3MBTL1ALDH1A1MAPTMEN1KMT2A
SCHEMBL19590931 0.73 HRH3 (0.50) L3MBTL1ALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 L3MBTL1 3599/4885ALDH1A1 1934/4885MAPT 4880/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 L3MBTL1 3097/4885ALDH1A1 2376/4885MAPT 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.